← ANALYST RATINGS · TIPRANKS

enGene Holdings (ENGN): analyst forecast and price target

$1.67 −2.34% close 16.10.26 · market cap $115M · Healthcare · Biotechnology
Price targets and ratings of

Analyst consensus

Hold

1 Buy4 Hold1 Sell

Ratings of 6 analysts in the last 3 months

12-month forecast

$2.80+67.7% upside

Based on 6 price targets given in the last 3 months, the average target is $2.80, the highest $4.00, the lowest $2.00. The average is +67.7% from the last price of $1.67.

$5.00$10.00Jan 26AprJulOctJan 27AprJulOctHigh$4.00Average$2.80Low$2.00
Highest target $4.00 Average target $2.80 Lowest target $2.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Allison Bratzel★★★★★★★★★★#171 · hits 64% · avg +41.9% Piper Sandler $4.00 Hold +139.5% Reiterated 16.10.26on TipRanks 07:35 −1.2%
Andres Y. Maldonado★★★★★★★★★★#149 · hits 58% · avg +42.1% H.C. Wainwright $4.00 Buy +139.5% Reiterated 16.10.26on TipRanks 06:35 −1.2%
Yanan Zhu★★★★★★★★★★#1136 · hits 36% · avg +15.3% Wells Fargo $2.00 Hold +19.8% Reiterated 02.10.26on TipRanks Oct 5 07:36 −2.8%next day −4.3% · 5 days −12.0%
David Dai★★★★★★★★★★#2876 · hits 59% · avg +9.3% UBS $2.00 Hold +19.8% Assigned 16.09.26on TipRanks 07:55 +1.5%next day −1.1% · 5 days +2.6%
Mani Foroohar★★★★★★★★★★#11266 · hits 43% · avg −2.1% Leerink Partners $2.00 Hold +19.8% Reiterated 09.09.26on TipRanks 08:35 −3.2%next day −3.7% · 5 days +4.3%
Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% Morgan Stanley — Sell — Reiterated 12.08.26on TipRanks 09:25 −6.8%next day −1.3% · 5 days +9.3%
Michael Schmidt★★★★★★★★★★#126 · hits 58% · avg +31.7% Guggenheim — Hold — Reiterated 16.06.26on TipRanks 06:55 −0.5%next day +0.7% · 5 days +2.0%
Sean McCutcheon★★★★★★★★★★#1382 · hits 43% · avg +39.7% Raymond James $27.00 → $4.00−85.2% Buy +139.5% Reiterated 08.05.26on TipRanks 05:20 −13.6%next day −0.9% · 5 days +14.5%
Silvan Tuerkcan★★★★★★★★★★#731 · hits 43% · avg +16.6% Citizens JMP — Hold — Downgrade 08.05.26on TipRanks 05:05 −13.6%next day −0.9% · 5 days +14.5%
Xin Yang NG‏ USmart Securities $21.50 Buy +1,187.4% Initiated 13.04.26on TipRanks 23:30 +1.1%next day +1.3% · 5 days +10.6%
Maury Raycroft★★★★★★★★★★#1326 · hits 44% · avg +12.0% Jefferies $28.00 Buy +1,576.6% Reiterated 25.02.26on TipRanks 10:55 +2.4%next day −0.1% · 5 days −2.4%

The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included

Best analysts covering enGene Holdings

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Andres Y. Maldonado★★★★★★★★★★H.C. Wainwright · #149
Hits 58%158 of 274 Average return +42.1%
1 year Andres Y. Maldonado★★★★★★★★★★H.C. Wainwright · #149
Hits 58%158 of 274 Average return +42.1%
2 years Andres Y. Maldonado★★★★★★★★★★H.C. Wainwright · #149
Hits 58%158 of 274 Average return +42.1%

Most profitable

3 months Judah Frommer★★★★★★★★★★Morgan Stanley · #2495
Hits 56%168 of 302 Average return +5.3%
1 year Andres Y. Maldonado★★★★★★★★★★H.C. Wainwright · #149
Hits 58%158 of 274 Average return +42.1%
2 years Andres Y. Maldonado★★★★★★★★★★H.C. Wainwright · #149
Hits 58%158 of 274 Average return +42.1%

Recommendation trend

051015208Oct 25151Nov141Dec161Jan 2610Feb711Mar811Apr1019May7111Jun4111Jul242Aug231Sep351Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy1074223
Buy100000
Hold91111435
Sell011211

Earnings and sales forecast

Next report: 23.12.26 (Q4 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $-0.46 (from $-0.55 to $-0.37). Last quarter: $-0.47.

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworksStrong Buy
About enGene Holdings
  • CEO: Ronald H. W. Cooper
  • Employees: 82
  • 4868 Rue Levy, Montreal, QC, H4R 2P1, CA
  • www.engene.com

Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.

Data from the stock’s TipRanks forecast page, read 64 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗